Investigating Bezisterim for Neurological Symptoms of Long COVID: The Phase 2 ADDRESS-LC Study
Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.
Welcome to NeurologyLive®'s Clinical Trial in Focus. Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. This month’s spotlight is the phase 2 ADDRESS-LC study (NCT06847191), a unique study assessing the therapeutic potential of bezisterim (BioVie), a blood brain barrier-permeable, insulin-sensitizer, as a treatment for patients with neurological symptoms associated with Long COVID.1